Buscopan Boehringer injection drug treatment for gastric and intestinal spasms (2 blisters x 5 tubes)

Dosage form Box of 2 blisters x 5 tubes x 10ml
Specifications Hyoscin Butylbromid
Ingredient Gastric, intestinal spasm, genital spasm, uterine spasms

Ingredient

Composition information	Content
Hyoscin Butylbromid	20mg/ml

Uses

Indications

Buscopan drugs are indicated in the following cases:

Treatment of gastric - intestinal spasms, bile and acute genitals, including bile and kidney pain.

ATC code: A03BB01.

The active ingredient in Buscopan is Hyoscine - N - Butylbromide, a known anti -spasm. The drug reduces pain by acting on spasms causing pain.

Hyoscine - N - Butylbromide has the effect of anti -muscle spasms of the stomach - intestines, biliary tract and urinary tract. As a quadratic ammonium derivative, Hyoscine Butylbromide does not enter the central nervous system. Therefore, the side effect of cholinergic resistance in the central nervous system does not occur. The peripheral anti -cholinergic resistance is the result of the nerve -blocking effect in the organs as well as from Muscarinic resistance.

pharmacokinetic

absorption and distribution:

After intravenous injection Hyoscine Butylbromide is quickly distributed into the tissues (t ½α = 4 minutes, t ½β = 29 minutes). The distribution volume (VSS) is 128 L (equivalent to about 1.7 l/kg). Due to high affinity with Muscarinic receptors and nicotinic receptors, Hyoscine Butylbromide is mainly distributed on muscle cells of the abdominal and pelvic area as well as in the inner lymphoma of the abdominal organs.

Linking with plasma protein (albumin) of Hyoscine Butylbromide is about 4.4%. Animal studies prove that Hyoscine Butylbromide does not surpass the brain barrier, but there is no clinical data for this effect. Hyoscine Butylbromide (1 mm) has been observed in interaction with the transport of choline (1.4 nm) in epithelial cells of the In vitro placenta.

Metabolism and elimination:

The main metabolic path is the ester hydrolysis. The sale time of the last removal phase (T ½γ) is about 5 hours. The total clearance is 1.2 l/min. Clinical studies with Hyoscine Butylbromide are marked with radioactive, showing that after intravenous injection, 42 - 61% of the radioactive dose is eliminated through the kidneys and 28.3 - 37% by fecal line.

The intact form is excreted in the urine is about 50%. The metabolites are excreted by the kidneys that are poorly connected to the muscarinic receptors and therefore are not considered to contribute to the effect of Hyoscine Butylbromide.

Before taking Buscopan Boehringer injection drug treatment for gastric and intestinal spasms (2 blisters x 5 tubes)

How to use

The drug is used slowly, intramuscularly, intramuscularly or subcutaneous injection.

Dosage

Do not use Hyoscine - N - Butylbromide (Buscopan) continuously daily or for a long time without understanding the cause of abdominal pain.

Adults and teenagers over 12 years old:

Inject 1 - 2 buscopan tubes (equivalent to 20 - 40 mg) several times a day.

Maximum daily dose must not exceed 100 mg.

infants and children:

In severe cases: injection 0.3 - 0.6 mg/kg body weight several times a day.

Maximum daily dose must not exceed 1.5 mg/kg body weight.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

Symptoms:

In case of an overdose, the patient may have anti -cholinergic effect.

Treatment:

If necessary, should use sympathetic medicine.

Need to be diagnosed by an ophthalmologist if an acute glaucoma occurs. Cardiovascular complications should be treated according to common treatment principles. In case of respiratory paralysis must put internal traches, artificial respiration.

may have to be placed in urinary catheter when urinary retention. In addition, it is necessary to use appropriate support measures as required.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Buscopan, you may experience unwanted effects (ADR).

Unknown frequency

Immune: Anaphylaxis can lead to death, anaphylactic reaction, shortness of breath, skin reaction (such as urticaria, rash, erythema, itching) and other sensitivity.

heart: tachycardia. digestive: dry mouth.

Skin and subcutaneous tissue: sweat disorders.

Kidney and urinary: Urinary retention. Eye: Eye regulatory disorders, pupils, glaucoma. blood vessels: reduced blood pressure, dizziness, redness.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Contraindicated

Buscopan drugs contraindicated in the following cases:

Patients with hypersensitivity to Hyoscine - N - Butylbromide or any other ingredient of the drug. can occur in the muscle). In these patients, subcutaneous or intravenous injection can be used.

Precautions when used

In case of severe abdominal pain, unknown cause/severe cause/severe, or appearing with symptoms such as fever, nausea, vomiting, changing bowel movement, abdominal pain, reducing blood pressure, fainting or blood in the feces, it is necessary to have appropriate diagnostic measures to investigate the originals of symptoms.

Due to the potential risk of anti -cholinergic complications, it is cautious when used for patients who are prone to narrow -angle glaucoma as well as prone to intestinal or urinary tract obstruction and in patients tending to tachycardly.

Object hypertrophy can onset when using anti -cholinergic drugs such as Hyoscine - N - Butylbromide (Buscopan) in patients with narrow -angle glaucoma that have not been diagnosed and treated. Therefore, patients should go to the doctor's doctor immediately in case the eye is painful, red and vision loss after injection Hyoscine - N - Butylbromide (Buscopan).

After injection Hyoscine - N - Butylbromide (Buscopan), cases of anaphylaxis include shocks that have been reported. As with all such drugs, it is necessary to closely monitor patients using Hyoscine - N - Butylbromide (Buscopan) through the injection.

Be careful and regularly monitor patients with heart disease being treated with Buscopan through the injection.

The ability to drive and operate machinery

There has been no research on the ability to drive and use machinery. However, patients should be warned about the possibility of unwanted effects such as eye regulation or dizziness during treatment with Hyoscine - N - Butylbromide injection (Buscopan). Therefore, it is necessary to be cautious when driving a car or operating machinery. If the patient has an eye regulation or dizziness, avoid jobs that can be dangerous.

Pregnancy

There are some limited data on the use of hyoscine butylbromide in pregnant women. Animal studies do not indicate directly or indirectly harmful effects related to reproductive toxicity.

Breastfeeding period

There is not enough information about the excretion of Hyoscine - N - Butylbromide (Buscopan) and its metabolites in breast milk. For prevention, it is best to avoid using Hyoscine - N - Butylbromide (Buscopan) during pregnancy and nursing.

Drug interaction

The anti -cholinergic effect of drugs such as antidepressants - and tetracyclic, antihistamine, psychotic anti -dysplasia, quinidine, amantadine, disopyramide and other anticholic drugs (such as Tiotropium, ipratropium, Atropine substances that can be increased) Cuong by Hyoscine - N - Butylbromide.

Concentrated treatment with dopamine antagonists like Metoclopramide can reduce the effect of both drugs on the digestive tract.

Effects on the tachycardia of beta - adrenergic agents that can be enhanced by Hyoscine - N - Butylbromide (Buscopan).

Storage

Store at a temperature not exceeding 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.